Why P2B001

Publications & Presentations

P2B001 Publications
  1. Olanow CW et al. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson’s disease. Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941.
  2. Hauser RA et al. P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2.
  3. Olanow WG. Efficacy and safety of P2B001 in the management of early Parkinson’s disease. Results from a phase 3, randomized, double-blind, double-dummy controlled trial.

  4. Olanow WG. P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial.

P2B001 Presentations
  1. Patient outcomes with P2B001: Phase 3 top-line results. Prof. C Warren Olanow

  2. Why we need more treatment options for early-stage Parkinson’s disease? Prof. Robert A. Hauser